Suven Life Sciences secures two product patents in Australia and Canada

19 Feb 2016 Evaluate

Suven Life Sciences has secured two product patents; one product Australia and one product patent from Canada corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2032 and 2031 respectively.

The granted claims of the patent from Australia include the class of selective 5-HT4 compounds and the granted claims of the patent from Canada is through mechanism of action - H3 Inverse agonist and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.

With these new patents, the company has a total of twenty three granted patents from Australia and twenty two granted product patents from Canada. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.

Suven Life Sciences Share Price

134.00 -2.90 (-2.12%)
23-Jan-2026 13:55 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1633.65
Dr. Reddys Lab 1237.55
Cipla 1305.30
Zydus Lifesciences 880.35
Lupin 2143.90
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×